RASSF1 and non-small cell lung carcinoma: However, the results of the Phase 3 IFCT (Intergroupe Francophone de Cancérologie Thoracique)-0002 randomized trial demonstrated both the prognostic and predictive values of RASSF1A gene silencing, following neo-adjuvant chemotherapy in patients with Stage I–II NSCLC [3].